US Stock Market Move | Treatment of genetic bone diseases in the research drug clinical trial failed, Ultragenyx Pharmaceutical (RARE.US) plunges over 42% in pre-market trading.
As of the filing, the stock is down over 42%, trading at $19.69.
Before Monday's US stock market opening, Ultragenyx Pharmaceutical (RARE.US) stock price plummeted. As of press time, the stock has fallen more than 42% to $19.69. On the news front, the company announced that its investigational drug for treating a specific genetic bone disease did not meet the primary efficacy endpoint in late-stage clinical trials.
Related Articles
Guosen: RWA welcomes the era of strict supervision.
Wondershare Technology Group (300624.SZ) has upgraded its Wondershare Filmora desktop version: free video editing, better AI results!
Northeast: Music ecosystem giant NETEASE MUSIC (09899) benefits from rapid industry growth.
Guosen: RWA welcomes the era of strict supervision.
Wondershare Technology Group (300624.SZ) has upgraded its Wondershare Filmora desktop version: free video editing, better AI results!
Northeast: Music ecosystem giant NETEASE MUSIC (09899) benefits from rapid industry growth.
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
